Chronic obstructive pulmonary disease and risk of infection.

This review article focuses on the risk of infections in patients with chronic obstructive pulmonary disease (COPD). Throughout the years there have been a number of studies describing the risk of pulmonary infections in patients with COPD, whereas only few studies have focused on the risk of infection outside the lungs. With increasing severity of COPD the risk of respiratory tract infection also increases. The impairment of the innate immune system is most likely responsible for both the colonization of respiratory tract with bacteria and for an increased risk of infection with new strains of bacteria causing acute exacerbations. Also lung infections like pneumonia, lung abscess and empyema are more often seen in patients with COPD than in healthy subjects. With regard to extrapulmonary infections, it seems that COPD patients are not at higher risk of infection compared with subjects without COPD. It is concluded that COPD is significantly associated with an increased risk of various respiratory tract infections, but not with infections outside the respiratory system.

[1]  T. Murphy,et al.  Infection in the pathogenesis and course of chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[2]  J. Vestbo,et al.  COPD stage and risk of hospitalization for infectious disease. , 2008, Chest.

[3]  A. Gonzalez,et al.  Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. , 2007, American journal of respiratory and critical care medicine.

[4]  J. Dollerup,et al.  The cost of treating patients with COPD in Denmark--a population study of COPD patients compared with non-COPD controls. , 2007, Respiratory medicine.

[5]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[6]  C. Mathers,et al.  Projections of Global Mortality and Burden of Disease from 2002 to 2030 , 2006, PLoS medicine.

[7]  Alan D. Lopez,et al.  Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data , 2006, The Lancet.

[8]  J. Wedzicha,et al.  Effect of Interactions Between Lower Airway Bacterial and Rhinoviral Infection in Exacerbations of COPD , 2006, Chest.

[9]  J. Hogg,et al.  Convergence of the epidemiology and pathology of COPD , 2005, Thorax.

[10]  J. Wedzicha,et al.  Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[11]  Andy Haines,et al.  Cold weather and GP consultations for respiratory conditions by elderly people in␣16 locations in the UK , 2004, European Journal of Epidemiology.

[12]  P. Poole,et al.  Prophylactic antibiotic therapy for chronic bronchitis. , 2013, The Cochrane database of systematic reviews.

[13]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[14]  J. Garcia-Aymerich,et al.  Bacterial infection in exacerbated COPD with changes in sputum characteristics , 2003, Epidemiology and Infection.

[15]  S. Hurd,et al.  Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update , 2003, European Respiratory Journal.

[16]  J. Wedzicha,et al.  Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[17]  J. Garcia-Aymerich,et al.  Risk factors of readmission to hospital for a COPD exacerbation: a prospective study , 2003, Thorax.

[18]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[19]  B. Grant,et al.  New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. , 2002, The New England journal of medicine.

[20]  W. Bailey,et al.  Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution , 2023, Medical science monitor : international medical journal of experimental and clinical research.

[21]  T. Seemungal,et al.  Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[22]  E Monsó,et al.  Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. , 2001, American journal of respiratory and critical care medicine.

[23]  N. Anthonisen,et al.  Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. , 2001, American journal of respiratory and critical care medicine.

[24]  M. Miravitlles,et al.  Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. , 2001, The European respiratory journal.

[25]  R. Stockley,et al.  Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. , 2000, Chest.

[26]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[27]  J. Wadsworth,et al.  Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. , 2000, Respiratory medicine.

[28]  Joan Wilson,et al.  Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[29]  M. Miravitlles,et al.  Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. , 1999, Chest.

[30]  K. Nichol,et al.  Relation between Influenza Vaccination and Outpatient Visits, Hospitalization, and Mortality in Elderly Persons with Chronic Lung Disease , 1999, Annals of Internal Medicine.

[31]  I. Bolíbar,et al.  Risk factors for community-acquired pneumonia in adults: a population-based case-control study. , 1999, The European respiratory journal.

[32]  J. Vestbo,et al.  Chronic mucus hypersecretion in COPD and death from pulmonary infection. , 1995, The European respiratory journal.

[33]  P. Schnohr,et al.  Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. , 1990, Thorax.

[34]  R. Kanner,et al.  Variables associated with changes in spirometry in patients with obstructive lung diseases. , 1979, The American journal of medicine.

[35]  R. Peto,et al.  The natural history of chronic airflow obstruction. , 1977, British medical journal.

[36]  W. Jędrychowski.  Sickness absence caused by chest diseases in relation to smoking and chronic bronchitis symptoms. , 1976, British journal of industrial medicine.